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ABSTRACT	  
 
 
In this synthesis I provide an overview on my scientific activity during more than 
10 years. The main transversal topic connecting all scientific projects in which I 
participated, is cell molecular mechanisms implicated in human disorders. Trained 
as biologist, I have dedicated first part of my career to studying neurodegenerative 
mechanisms. Whereas, in the second part of my career I focused on deciphering 
complexity of cancer mechanisms by computational systems biology approaches, 
which is my current scientific activity, also reflecting the future interest. Four 
chapters of the synthesis chronologically describe the major areas of my interest:  
Chapter 1 is dedicated to the experimental part of the work on 
mechanisms of neurodegeneration, with focus on oxidative stress signaling and 
synaptic toxicity in Alzheimer’s disease. 
 
Chapters 2-4 are devotes to the work in the field of systems biology of cancer and 
represent sequential steps of multidisciplinary project on signaling rewiring in 
cancer and new therapeutic intervention schemes development: 
Chapter 2 describes how to address complexity of cancer by systematic 
representation of signaling implicated in the disease in the form of comprehensive 
signaling network maps and impact of this approach on interpretation of cancer 
omics data. 
Chapter 3 summarizes studies on application of signaling networks 
modeling for finding synthetically interacting genes in cancer; predicting drug 
synergy and suggesting complex therapeutic intervention sets. 
Chapter 4 deals with more fundamental topic of mechanistic principles in 
synthetic lethality. The first part is dedicated to new synthetic lethal paradigm that 
we suggested following modeling studies. In the second part, I discuss synthetic 
lethal mechanisms at several scales of intra- and inter-cellular signaling, from 
molecules to functional modules in cell and toward synthetic interactions between 
different cell types.  
 
The synthesis is concluded by describing challenges and future directions in the 
field of signaling rewiring studies in human disorders, articulating the 
complementarity of experimental and computational approaches. 
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RESUMÉ	  [FRENCH]	  
 
ETUDE DES RESEAUX DE SIGNALISATION DANS LES MALADIES 
HUMAINES   
Dans ce mémoire je présente un panorama de mon activité scientifique depuis plus de 
dix ans. Le principal axe transversal reliant tous les projets scientifiques auxquels j’ai 
participé est celui des mécanismes moléculaires de la cellule impliqués dans les maladies 
humaines. Biologiste de formation, j’ai dédié la première partie de ma carrière à l’étude 
des mécanismes neurodegénératifs, tandis que la seconde partie a été consacrée à l’étude 
de la complexité des mécanismes du cancer par des approches computationnelles de 
biologie des systèmes. Ces derniers constituent mon activité scientifique actuelle et mon 
centre d’intérêt futur. Les quatre chapitres de mon mémoire décrivent dans l’ordre 
chronologique mes domaines majeurs d’intérêt:  
Le chapitre 1 est dédié à la partie experimentale de mon travail sur les 
mécanismes de neurodégénération, avec un focus sur le stress oxydatif signaling et la 
toxicité synaptique dans la maladie d’Alzheimer. 
 
Les chapitres 2-4 sont consacrés au travaux dans le domaine de la biologie des systèmes 
du cancer et représentent les étapes successives d’un projet multidisciplinaire d’étude des 
réseaux de signalisation du cancer et de la recherche de nouveaux schémas 
d’intervention thérapeutique: 
Le chapitre 2 décrit d’une part comment appréhender la complexité du cancer 
par une représentation systématique de la signalisation impliquée dans cette maladie, 
sous la forme de cartes aussi complètes que possible du réseau de signalisation; il montre 
d’autre part l’impact de cette approche sur l’interprétation de données omiques de 
tumeurs.  
Le chapitre 3 résume les études utilisant la modélisation de réseaux de 
signalisation pour trouver les gènes en interaction synthétique dans le cancer, prédire les 
synergies entre drogues, et proposer des schémas complexes d’intervention 
thérapeutique. 
Le chapitre 4 aborde de façon plus fondamentale les principes mécanistiques de 
l’interaction létale synthétique. La première partie porte sur un nouveau paradigme 
d’interaction synthtique que nous avons suggéré suite à une étude de modélisation 
mathématique. Dans la seconde partie, je discute les mécanismes de létalité synthétique à 
différentes échelles de signalisation intra- et inter-cellulaire, de la molécule aux modules 
fonctionnels de la cellule, et jusqu’aux interactions synthétiques entre différent types 
cellulaires.  
Le mémoire se conclut par la description des défis et directions futures dans le domaine 
des réseaux de signalisation des maladies humaines, s’appuyant sur la complémentarité 
des approches experimentales et computationnelles. 
 
  
 5 
PREFACE	   	   	   	   	   	   	   	   	  
 
                    Dedicated to the respected and beloved ones 
 
The knowledge of cell molecular mechanisms implicated in human diseases is 
expanding and should be converted into guidelines for deciphering pathological 
cell signaling and suggesting appropriate treatment. The basic assumption is that 
during a pathological transformation, the cell does not create new signaling 
mechanisms, but rather it hijacks the existing molecular programs. This affects not 
only intracellular functions, but also a crosstalk between different cell types 
resulting in a new, yet pathological status of the system. There is a certain 
combination of molecular characteristics dictating specific cell signaling states 
that sustains the pathological disease status. Identifying and manipulating the key 
molecular players controlling these cell signaling states, and shifting the 
pathological status toward the desired healthy phenotype, are the major challenge 
for molecular biology of human diseases. 
 
From the beginning of my career I have been interested in understanding the 
mechanistic basis of biological functions. Going from the detailed information 
about cell signaling to an abstract model is the way to find regularities in the 
functioning of a biological system. I strongly believe that a combination of 
knowledge about emerging principles of a biological system behavior, together 
with specific molecular perturbations in each patient will help to come up with 
individual intervention schemes. 
 
The projects depicted in this synthesis represent a combination of my expertise in 
experimental sciences, specifically cell signaling, with computational systems 
biology. Each scientific project inevitably requires development of new 
appropriated methods. Thus, the description of my work combines together the 
methodological and the scientific achievements. 
 
My diverse arsenal of knowledge and methods is an asset for multidisciplinary 
studies represented in this document and also for the ongoing and future to-come 
projects. Among others, my scientific role is to bring together biologists, 
clinicians, biostatisticians and developers to match various approaches to the 
current scientific challenges. 
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INTRODUCTION	  
 
 
Neurodegenerative diseases as Alzheimer´s, Parkinson, Huntington´s and cancer 
are two common chronic disorders in the elderly. Neurodegeneration is 
characterized by progressive dysfunction and eventual loss of neurons, whereas 
cancer is associated with uncontrolled and excessive cell proliferation. Therefore, 
these two types of disease seem to be on opposite ends of the cell growth 
regulation spectrum. Indeed, inverse association between neurodegeneration and 
cancer has been observed (Lin et al., 2015, Thinnes, 2012). 
 
The initiation of these diseases has a different nature. Neurodegeneration is 
associated with increased synaptic and neurotoxicity eventually leading to 
neuronal death, either caused by, or concomitant with, protein misfolding, 
aggregation and deposition in the brain tissue (Lim and Yue, 2015). Conversely, 
in cancer, oncogene activation and accumulation of mutations disrupts cell 
regulation mechanisms resulting in augmented cell survival and/or proliferation 
(Wade and Wahl, 2006).  
 
During the disease progression multiple and probably common molecular 
mechanisms are getting involved, but these processes are regulated in an opposite 
manner in the two disorders. It is obvious that perturbations of mechanisms 
involved in cell survival and death regulation are affected differently. Therefore it 
is important to delineate what are the “switch mechanisms” determining the 
decision to “die” in the case on neurodegeneration or “repair and live”, in the case 
of cancer. There might be genetic polymorphisms, or epigenetic mechanisms 
determining a predisposition to malfunction of an underlying common 
mechanism, dictating prone-to-death state of cells (‘neurodegenerative 
phenotype’) or prone-to-survive/grow state of cells (‘cancer phenotype’). Thus, in 
the ‘neurodegenerative phenotype’, cell may be susceptible to cell death stressors 
such as aggregated proteins, hyperphosphorylation, oxidation, inflammation or 
other unknown risk factors. Conversely, cells would have a greater likelihood of 
surviving under stressors, while concomitantly becoming more susceptible to 
cancer development if they are bearing the ‘cancer phenotype’ (Behrens et al., 
2009). There are several key players in the cell signaling that are discussed in the 
literature as candidate ‘switchers’ among others, p53, WNt, Pin1, that coordinate 
between cell cycle to cell death and regulated in cancer and in neurodegeneration 
in an opposite manner. In addition, it is important to keep in mind that more and 
more cell functions are discovered to be associated with each one of these 
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disorders, as immune response, angiogenesis, metabolic pathways, etc. (Heppner 
et al., 2015, La-Beck et al., 2015). These observations are pointing to importance 
of analysis and comparison of these two disorders at the higher level of signaling 
rewiring, taking into account the whole complexity of signaling network inside the 
cell and also investigating the impact of different biological functions, provided by 
interplay between various cell types. 
 
Alzheimer’s	  disease:	  a	  disorder	  of	  protein	  misfolding	  and	  synaptic	  
failure	  	  
 
Alzheimer´s disease (AD) is age-related neurodegenerative disorder characterized 
by accumulation of neurotoxic misfolded and aggregated amyloid-beta peptides 
(Aβ). The Aβ peptides form pathogenic assemblies ranging from small oligomers 
to large masses of amyloid and each state of the aggregation is characterized by 
different toxicity potential. Once believed to be brain region-specific and static, 
these protein aggregates have been recently shown to propagate their 
conformation through the brain. The outcome of Aβ accumulation is functional 
compromise of the nervous system.  
 
It is still open question, which are the critical toxic misfolded assemblies initiating 
synaptic dysfunctions, whether oligomers or larger aggregates? What are the 
precise molecular mechanisms initiating dysfunctions of synapses and neural 
circuits? What is the role of additional biological systems e.g. vascular, immune, 
in the neurodegeneration? Whether some processes are reversible and whether 
preventive actions are possible to preclude Aβ accumulation and consequent 
neurodegeneration?  
 
These questions are mostly addressed experimentally and examples of some 
discoveries are discussed in the Chapter 1. In addition, since there is more and 
more available omics data accumulated by high-throughput technologies and 
pieces of information describing various aspects of AD signaling, systems biology 
approaches gaining importance in the AD research (Xia et al., 2014, Santiago and 
Potashkin, 2014). 
 
Cancer:	  	  a	  systems	  biology	  disorder	  	  
 
Molecular biology of cancer has witnessed two parallel evolutions in the last 
decades, which are complementary and together contributed to our understanding 
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of the biological mechanisms of the pathology, and to the evolution of its clinical 
treatment. The first of these evolutions is the careful work of biologists who have 
deciphered in great detail the intricacy of molecular mechanisms that govern 
tumor initiation and progression, and reported these discoveries in the form of 
scientific papers.  
 
The second evolution was made possible by the advent of high-throughput 
technologies like microarrays and later next-generation sequencing, allowing 
accumulation of molecular profiles of tumours, with exhaustive description of the 
mutational landscapes, gene expression patterns and epigenetic modifications for a 
large number of samples. Nearly, 20 000 tumour samples have been profiled so far 
by two main international efforts, The Cancer Genome Atlas (TCGA, 
http://cancergenome.nih.gov) and ICGC (http://icgc.org). These two evolutions 
have contributed to precision oncology, which can be defined as the use of 
molecular profiles of tumours and constitutional genome to orient the choice of a 
therapy for a given patient (Topol, 2014, Berns and Bernards, 2012).  
 
However, despite availability of the omics data there is still no clear understanding 
of molecular mechanisms that would explain a correlation between the data and 
particular phenotypes in each case. Taking into account the information about 
biological signaling machinery in cells may help to better interpret the patterns 
observed in omics data of tumours. This will allow rationalized medicine approach 
for patients stratification, drug response prediction and treatment assignment 
(Barillot et al., 2012, Calzone et al., 2014). 
 
To enable data analysis in the context of molecular mechanisms, the information 
on these mechanism should be systematically and adequately represented. The 
knowledge about molecular signaling mechanisms in cells is dispersed in 
thousands of publications, mostly in human-readable form precluding application 
of methods and algorithms developed in the field of bioinformatics and systems 
biology. There is a need in formalized compilation of the knowledge in a 
computer-readable form. The current solution is representation of relationships 
between cellular molecules in a form of pathway diagrams found in various 
pathway databases (Chowdhury and Sarkar, 2015, Bauer-Mehren et al., 2009).  As 
the amount of information about biological mechanisms steadily increases, a 
different approach for organization, and structuring of this data is essential. The 
aim is to create more global picture of cell signaling with sufficient granularity of 
molecular details representation, capturing crosstalks and feedback loops between 
molecular circuits. For this purpose, comprehensive signaling network maps 
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covering multiple cellular processes simultaneously are more suitable than 
disconnected pathway diagrams. Our advances and contribution to this field are 
discussed in the Chapter 2.1.  
 
Visualization and analysis of omics data in the context of signaling networks 
allows better interpretation of the data and verification of deregulated mechanisms 
(Carter et al., 2013, Krogan et al., 2015). Several developments facilitating 
visualization and analysis of high-throughput data are shown in the Chapter 2.2. 
   
Furthermore, data analysis in the context of signaling networks can help to detect 
data distribution patterns across molecular mechanisms on the signaling maps, 
verifying network variables as enriched functional modules (‘hot’ deregulated 
areas), key players, ‘bottleneck’ points (Wang et al., 2015). Correlating those 
network variables with the phenotype, as drug resistance or patient survival, 
followed by clustering methods allows to stratify patients according to their 
integrated network-based molecular portraits and to suggest appropriate 
intervention scheme (Dorel et al., 2015). Application of signaling network to 
explain mechanism of drug action in cancer is shown in Chapter 3.1. 
 
Structural analysis and modeling of different scenarios (e.g. mutants, fusion, sub-
cellular re-localization) using networks allow to verify synthetic interactions 
between molecular players, explain phenotypes and rise a hypothesis for 
experimental validation (Cohen et al., 2013). How in silico studies of cell 
signaling can lead to mechanistic predictions, validated in the experimental model 
is discussed in Chapter 3.2. 
 
The extreme case of negative synthetic interaction is synthetic lethality (SL). The 
classical paradigm explains synthetic lethal interactions as a phenomena where 
combinations of two gene deletions significantly affects cell viability, whereas 
single deletion of each one of those genes does not (Kaelin, 2005). Synthetic 
lethality (SL) provides a conceptual framework for the development of cancer-
specific drugs. The idea of SL treatment approach is to take an advantage of the 
specificities in tumor cells which bearing abnormal function of one of the genes 
from the synthetic lethal pair. Targeting synthetic lethal partner allows then 
selective killing of tumor cells, and avoiding or limiting side effects on normal 
cells (Fang, 2014). 
 
The attempt to identify SL pairs in different cancers can be addressed in several 
ways. For example, experimental approaches may include classical study of 
 10 
molecular mechanism using knockout cell or animal models. Additional, wider 
approach is high-throughput screens of synthetic lethality using siRNA, shRNA or 
CRISPR/Cas9 technologies. The sub-set of this method is gene-drug synthetic 
lethality screening aiming to retrieve genes-sensitizers for the drug. Those 
methods already provided a bunch of information of SL gene and gene-drug pairs 
and lead to generation of SL databases and networks (Measday et al., 2005, Ooi et 
al., 2006). Several SL targets are assumed as druggble for some cancers (Fece de 
la Cruz et al., 2014). However, the experimental methods are time and resources 
consuming and can cover only limited number of SL pairs. Another very 
significant drawback of these approaches is that they address only pairwise SL 
interactions, but not bigger SL sets.  
 
According to the current understanding, signaling pathways create a complex 
network with forward and backward regulatory loops, and many redundant 
pathways, therefore the synthetic lethality pairs paradigm should be extended to 
the synthetic lethal sets or combinations paradigm (Garg et al., 2013, Huang et al., 
2014). Increasing number of synthetically interacting players above two would 
expand the experiments due to high number of possible combination that is 
unachievable. The alternative (or complementary) to the experimental is the 
computational approach that allows to test in silico multiple synthetic interactions 
combinations considering very big comprehensive signaling networks. Example of 
this approach application to suggest interventions sets inferred from network 
analysis with patient data is shown in Chapter 3.3.  
 
Data from SL screens and knowledge of signaling networks structure allows to 
infer the organizational principles of pathways and reduction of pathawys up to 
abstract models. These models are suitable for mathematical modeling to better 
understand the system’s properties and synthetic relationships between players in 
the model. Using this approach we performed in silico simulations that lead to 
discovery of new mechanism of SL, as described in Chapter 4.1. 
 
In addition, systematic representation of signaling in a form of networks, analysis 
and modeling collectively can provide enough material to try and retrieve 
emerging principle of signaling organization and to classify the spectrum of 
synthetic interactions, in particular synthetic lethality. Classification of synthetic 
interactions mechanisms at different scales of inter- and intracellular signaling is 
discussed in Chapter 4.2. 
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Similarly, aforementioned systems biology approaches exploiting comprehensive 
cell signaling network maps, can be useful for analyzing perturbations in cellular 
processes not only in cancer, but also in other human disorders, as immune 
diseases, stroke, cardiovascular diseases and neurodegeneration. 
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1.	  MOLECULAR	  MECHANISMS	  OF	  NEURODEGENERATION	  
 
 
CHAPTER	  AT	  GLANCE	  
The main player associated with Alzheimer's disease is amyloid-beta peptide (Aβ) which is 
aggregated and deposited in the brain tissues during the course of the disease. The chapter 
describes studies on the role of metal ions, oxidative stress and lipid composition on the 
physiological vs. cytotoxic potential of Aβ and regulation of neuronal phosphorylation cascades. 
Moreover, Aβ peptides vary in their lengths and the balance between different peptides types in 
the brain dictates their aggregation status. The synaptotoxic and cytotoxic potential of the 
aggregates and consequent effect on neuronal and cognitive functions are shown. The impact of 
these discoveries on therapeutic approaches in Alzheimer's disease is discussed.  
	  
1.1	   Phosphorylation	   cascades	   and	   oxidative	   stress	   response	   in	  
neurodegenerative	  diseases	  
The Weizmann Institute of Science, Rehovot, Israel 
 
Working hypothesis  
During my PhD, I've focused on studying mechanisms involved in oxidative stress 
response after stroke and consequent neurodegeneration during Alzheimer's 
disease (AD). It has been known, that the major inducers of neuronal loss in AD 
are amyloid-beta peptides (Aβ) that gaining neurotoxic properties while their un-
controlled accumulation and aggregation. In addition, the AD brains are 
characterized by increased oxidizes species content. Finally, the correlation 
between stroke incidents followed by oxidative response and induction of AD 
symptoms has been found (Zhao and Zhao, 2013). Therefore, the working 
hypothesis of the project was that oxidation-related processes might be connected 
to the Aβ-induced neurodegeneration, however the mechanism of action has to be 
elucidated.  
 
Methodologies 
Primary neuronal cell cultures, mice and rat stroke models were used to study oxidative stress 
in combination with additional stimuli as Aβ peptides or various pro- and anti-oxidant 
compounds. I have developed an in vivo method for combination of compound injection with the 
transient brain ischemia induction in mice and rat models by fine-tuned control of brain blood 
supply without direct brain surgical intervention. Phosphorylation cascades perturbations in 
cell models and in the brain tissue from mice and rat models were assessed using basic 
molecular biology techniques as Western blots, PCR, confocal imaging, antioxidants activity 
bio-assays, etc.  
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Results 
We have discovered that Aβ peptides, the main players in AD, have dual role in 
neuronal viability regulation and shown it in primary cell culture and in rat model. 
Aβ peptides can serve a neuroprotective role by ‘buffering’ the oxidation agents, 
but can be switched to neurotoxic compounds during prolonged oxidative stress. 
(Kuperstein and Yavin, 2003, Kuperstein et al., 2004). In addition, we have found 
bi-phasic regulation of phosphorylation signaling cascades in neurons involved in 
the switch mechanism from pro-survival to pro-degenerative (Kuperstein et al., 
2001, Kuperstein and Yavin, 2002). The study suggested the new concept of 
physiological role for Aβ peptide in neurons that has not been considered in the 
field before. In addition, we’ve demonstrated one of the possible molecular 
mechanisms involved in the oxidative stress-dependent neurotoxicity and neuronal 
death caused by Aβ peptides in their toxic state. These findings were used in 
development of a combinational treatment scheme in AD with anti-oxidant and 
anti-aggregation compounds together  (Figure 1). 
 
Figure 1. Dual role of Aβ on neuronal viability. Effect of different Aβ peptides in presence or 
absence of metals ions on (A). mitochondrial activity and (B). neuronal toxicity in cell culture, 
demonstrating that ions are promoting Aβ aggregation (not shown) and consequent 
neurotoxicity. (C). Physiological concentration of Aβ is neuroprotective against acquit oxidative 
stress in brain tissue.  (D). Kinase inhibitors are used to find out the key kinase pathway 
involved in the switch between cell survival and cell death.  
 
A" B"
C"
D
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In this collective work I coordinated technician and several students. The project resulted in 
four major publications, number proceedings publications and collaboration with the pharma 
start-up company for development of anti-AD treatment schemes. 
 
1.2	   Molecular	   mechanisms	   of	   synaptic	   and	   neuronal	   toxicity	   in	  
Alzheimer’s	  disease.	  
VIB-KU Leuven and IMEC-nanoelectronics and nanotechnology research center, Leuven, Belgium 
 
Working hypothesis 
During my post-doc, I've been involved in two international collaborative projects: 
(1). MEMOSAD-Verum European network for Memory Loss in Alzheimer's 
Disease: Underlying Mechanisms and Therapeutic Targets. The project aimed to 
study amyloid-beta peptides (Aβ) neurotoxic properties and modes of neuronal 
death in Alzheimer’s disease (AD). (2). ASAP-Artificial SynAPse consortium 
were I participated in design and development of nanoelectronic tool Artificial 
SynAPse for middle-throughput analysis of synaptic and neuronal toxicity. 
Artificial SynAPse device has been used during the studies on the neurotoxic 
potential of Aβ peptides, under the first project.  
Aβ peptides are deposited in the amyloid plaques in the brain tissue of AD 
patients. Therapeutic approaches attempt dissolving those plaques to reduce 
amyloid levels, considering that the deposits are drivers of the disease. However, a 
low correlation between the total burden of amyloid deposited in brain and the 
degree of neurodegeneration in the patients was found lately. AD brains contain 
heterogeneous mixture of Aβ peptides varying in length, modifications and 
aggregation potential. The local environment in vicinity of amyloid plaques may 
affect aggregation status of Aβ peptides (Breydo and Uversky, 2015). The 
working hypothesis of the study was that Aβ might have non-equal neurotoxic 
properties and induce various mechanisms of neurotoxicity depending on the 
mixture composition and aggregation status of the peptides in the brain. 
 
Methodologies 
Biophysical, biochemical and behavior approaches were applied. The mixtures of most 
abundant Aβ40 and Aβ42 peptides were prepared in various peptides ratios. Combinations of 
typical natural lipids were added to assess the role of plaques environment in Aβ aggregation. 
Conformational properties of aggregation species in Aβ mixtures were studied using the 
transmission electron microscopy (TEM) and Dynamic light scattering (DLS) methods. The 
aggregation/dissociation kinetics were measured by Fourier transform infrared spectroscopy 
(FTIR) and ThT fluorescence methods. Primary neuronal cultures were used to assess effect of 
Aβ mixtures on spontaneous synaptic activity recorded on the Artificial SynAPse device and 
using the patch-clamping techniques. The composition of synapses was visualized under the 
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confocal microscopy following the fluorescent staining of synaptic markers. The neurotoxicity 
was assessed using several viability and apoptotic assays. The cognitive and behaviour 
consequences of brain exposure to the Aβ mixtures were studied in mice models using learning 
and memory tests as open field-behaviour recording; passive avoidance and 
contextual/auditory-cue fear conditioning. Finally, distribution of Aβ species in the brain tissue 
was visualized using the immunofluorescent staining technique.   
 
Results 
Part I. It is assumed that Aβ aggregation reaction proceeds ‘forward’ in an 
irreversible manner from Aβ peptide to amyloid fibrils found in plaques. We’ve 
shown that natural lipids resolubilize amyloid fibrils toward small soluble highly 
neurotoxic Aβ species that diffuse through the brain and cause memory 
impairment. The balance between toxic and inert Aβ pools is determined in part 
by the relative amounts of lipids around the plaques. Therefore, the plaques should 
be considered as reservoirs of potential toxicity in AD. For example, stroke, 
trauma or any metabolic perturbations in the brain may result in release of free 
lipids initiating amyloid fibrils dissociation into toxic Aβ species. The results 
could also explain why the amount of amyloid deposits and the severity of 
associated disease symptoms in AD do not necessarily correlate (Martins et al., 
2008). In this study we introduced a new understanding of dynamics in the 
amyloid plaques in AD. The possibility that inert amyloid plaques could be turned 
into highly neurotoxic species should be considered while designing treatments for 
AD. Therefore the therapeutic strategies aiming at dissolving amyloid plaques 
should be critically revised (Figure 2). 
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Figure 2. Lipids induce disassembly of mature Aβ fibrils into soluble toxic oligomers. (A). 
Electron microscopy micrographs demonstrating lipid-induced dissociation of mature fibrils 
into oligomes that penetrate to the neuronal cells. (B). The purified fraction of Aβ oligomers 
(C). causes neuronal cell death and (D). learning and memory formation dysfunction in mice. 
 
Part II. Differences in neurotoxicity and consequent AD severity might be 
dictated by the equilibrium between the peptides in the Aβ pool. We have shown 
that a minor increase in the Aβ42:Aβ40 ratio stabilizes toxic Aβ species and 
activate mechanism of ‘synaptic apoptosis’ involving components of apoptotic 
machinery that extends lately to the whole cell apoptosis. In addition these Aβ 
species diffuse in the brain and interfere with learning and memory (Figure 3). 
The concept that the absolute quantity of Aβ peptides in the brain is less important 
than the relative Aβ peptides ratio in the pool reflected in their potential to 
generate stable highly neurotoxic Aβ species was suggested. The finding is 
important for development of new drugs type aiming to restore the correct ratios 
between Aβ peptides. This approach promises to lead to the treatment that will 
prevent neurotoxicity in AD, regardless the amount of Aβ found in the brain 
(Kuperstein et al., 2010). Following this work, development of new generation of 
drugs controlling Aβ conformation has been initiated in collaboration with a 
pharma company.   
A B 
C D
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Figure 3. The ratio between Aβ peptides of different length (A). dictates aggregation dynamics 
and toxic conformation of oligomers (B). interfering with synaptic firing, (C). synaptic structure 
and cell viability. 
Part III. Detecting effect of neurodegenerative agents at synapses is crucial for 
considering drugs that would protect synapses at early stages in neurodegenerative 
process. To allow such developments, synaptic functionalities have to be followed 
is a systematic way. I have participated in developing a new approach combining 
neurobiology and nano-scale engineering that lead to construction of Artificial 
SynAPse device. This neuro-electronic hybrid combines nanoelectronic chip with 
highly dense and sensitive electrodes; special bio-mimetic surfaces for neuronal 
growth-on-chip and elaborated signal processing system that allowed to scale 
down the size of recording area and increase number of recording spots and to 
improve signal recognition. Currently this and the next-generation Artificial 
SynAPse devices are used for drugs screening. This project has lead to initiation 
of the association Neuro-Electronics Research Flanders (NERF) 
(http://www.nerf.be).  
In these projects I coordinated the collaboration between the teams and supervised 
technician, students and post-doc involved in the projects. The projects resulted in publication 
of two major papers, several proceedings; press release on the discoveries; initiation of new 
drug development; release of nano-electronic device. The work was awarded by the Verum 
foundation prize. 
A B 
C
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2.	  CANCER:	  A	  COMPLEX	  SYSTEM	  
 
Institut Curie, Paris, France 
 
CHAPTER	  AT	  GLANCE	  
The chapter discusses formalization of biological knowledge into a comprehensive map as Atlas 
of Cancer Signaling Network (ACSN) and Google Maps-based tool NaviCell that supports map 
navigation. The application of maps for omics data visualization in the context of signaling 
maps by NaviCell Web Service module is shown. Finally, new tool NaviCom is presented, 
allowing generation of network-based molecular portraits of cancer using multi-level omics 
data. The chapter summarizes the achievements of multidisciplinary projects involving 
numerous collaborations. Ongoing efforts, future plans and perspectives are outlined. 
 
2.1	  Formalization	  of	  biological	  knowledge	  as	  signaling	  network	  maps	  
 
Working hypothesis  
Deregulation of molecular mechanisms leading to cancer concerns various 
processes such as cell cycle, cell death, DNA repair and DNA replication, cell 
motility and adhesion, cell survival mechanisms, mechanisms of immune system 
angiogenesis and tumor microenvironment.  Usually most of them are involved in 
the same tumor and modified as the tumor evolves. It is assumed that in 
pathological situations the normal cell signaling network is affected by 
deregulated coordination between pathways or disruption of existing molecular 
pathways, rather than by creating completely new signaling pathways and 
molecular interactions. The most common abnormalities in pathological situations 
are perturbations at the level of gene expression, protein abundance or protein 
posttranslational modifications, irregular ‘firing’ or silencing of particular signals, 
wrong sub-cellular localization of particular molecules and so on.  
Such quantitative rather than qualitative network changes compared with normal 
cell signaling could be studied in the context of comprehensive signaling networks 
by analyzing experimental data obtained from cancer samples, cancer-related cell 
lines or animal models. This approach helps to understand interplay between 
molecular mechanisms in cancer, deciphering how gene interactions govern 
hallmarks of cancer (Hanahan and Weinberg, 2011) in specific context and use 
this knowledge to stratify patients accordingly. This will lead to new therapeutic 
strategies, rationalizing the use of targeted inhibitors (Dorel et al., 2015).  
An advantage of representing the biological processes in a graphical form is 
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demonstrating collectively multiple cross-talks between components of different 
cell signaling processes. This allows understanding the global picture and 
connectivity between processes that is very difficult to keep in mind just from 
reading multiple scientific papers. Once the processes are depicted together as 
diagrams, the relationship between molecular circuits in cells can be appreciated, 
which makes signaling network maps also didactic tools. 
 
For computational systems biology of cancer, this approach dictates the following 
strategy: 1) represent formally and in sufficient amount of details the existing 
knowledge about those molecular processes whose involvement in cancer clearly 
demonstrated; 2) collect and integrate existing quantitative data on cancer genesis 
and progression and develop methods to analyze them in the light of the 
knowledge of a normal cell; 3) create mathematical models able to describe 
distortions of normal cell functioning as a cause of cancer, and to predict the effect 
of various perturbations; 4) use data analysis and mathematical modeling to 
suggest new therapeutic schemes. 
 
Despite existence of a large variety of pathway databases and resources 
(Chowdhury and Sarkar, 2015), only few of them depict processes specifically 
implicated in cancer and none of those resources depicts the processes with 
sufficient granularity. In addition, pathway browsing interfaces and data 
integration tools are not very advanced. The current project aims to formalize 
knowledge on cancer-related processes as comprehensive signaling network maps, 
developing algorithms for map navigation, data analysis in the context of maps 
and data interpretation for basic research and in clinical studies. 
 
Methodologies and Results 
Construction and update of Atlas of Cancer of Signaling Networks (ACSN) 
involves manual mining of molecular biology literature and participation of the 
experts in the corresponding fields (http://acsn.curie.fr). ACSN differs from other 
databases because it contains more comprehensive description of cancer-related 
mechanisms retrieved from the most recent literature, following the hallmarks of 
cancer. Cell signaling mechanisms are depicted using CellDesigner tool (Kitano et 
al., 2005) at the level of biochemical interactions, forming a large network of 4600 
reactions covering 1821 proteins and 564 genes and connecting several major 
cellular processes. Currently ACSN contains representation of molecular 
mechanisms that are frequently deregulated in cancer such as cell cycle, DNA 
repair, cell death, cell survival, and epithelial to mesenchymal transition (EMT). 
Cell signaling mechanisms are depicted on the maps in great detail, together 
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creating a seamless map of molecular interactions, presented in the form of a 
global ‘geographic-like’ molecular map (Figure 4A). ACSN has a hierarchical 
structure, composed of interconnected maps of biological process implicated in 
cancer. Each map is further contains functional modules mainly corresponding to 
canonically-defined signaling pathways (Figure 4C).  
The navigation interface include features such as scrolling, zooming, markers and 
callouts using Google Maps technology adopted by NaviCell (Kuperstein et al., 
2013). Semantic zooming in NaviCell (http://navicell.curie.fr), providing several 
view levels on maps achieved by gradual exclusion of details and abstraction of 
information upon zooming out (Figure 4B). ACSN is associated with a web-based 
blog system WordPress for collecting feedback from the community on content of 
the map that facilities maintenance and updating of ACSN (Kuperstein et al., 
2015).   
 
B"
C"
A 
B C
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Figure 4. Atlas of Cancer Signaling Networks. (A). Distribution of frequently mutated 
oncogenes across human cancers visualized on the ACSN maps; (B). Google-like features of 
NaviCell  for visualization and annotation of map entities; (C). Zoom in on a survival map to 
observe signaling processes. 
 
ACSN is a unique resource of signaling in cancer that did not exist in the field, the 
amount of information embedded and organized in ACSN is enormous. Together 
with NaviCell, it optimized for integration and visualization of cancer molecular 
profiles generated by high-throughput techniques, data from drug screenings or 
synthetic interactions studies. Integration and analysis of these data in the context 
of ACSN may help in understanding the biological significance of the results, 
guiding the scientific hypothesis and suggesting potential intervention points for 
cancer patients. In addition, since ACSN covers major cell signaling processes, the 
resource and associated methods for data analysis using ACSN are suitable for 
applications in many biological fields and for studying various human disease.  
 
The atlas is being extended with additional maps depicting molecular mechanisms 
of DNA replication, telomere maintenance, angiogenesis, immune response and 
others that will be integrated into future releases of the atlas. The atlas will cover 
not only intracellular, but also extracellular processes as tumor microenvironment. 
An additional level of complexity will be added to the atlas in a near future, 
representing different types of cells surrounding tumor, and interplay between 
them, to enable modeling of complex phenotypes. 
 
2.2	   Molecular	   portraits	   of	   cancer:	   data	   visualization	   and	   analysis	  
using	  signaling	  network	  maps	  	  
 
The data integration into the ACSN is possible using NaviCell Web Service, an 
user-friendly environment embedded into the NaviCell tool, allowing to upload 
several types of “omics” data (expression data for mRNA, microRNA, proteins, 
mutation profiles, copy-number data) and visualize them simultaneously in the 
context of molecular interaction maps. Depending on the nature of data, different 
types of visualization modes can be required to achieve the informative picture 
(heat maps, bar plots, glyphs and map staining). The data can be visualized at 
different zoom levels. Sample annotation files unloaded together with the data can 
serve for defining groups of samples. A novel mode of data visualization for 
continuous data (e.g. expression) provided by NaviCell Web Service is a ‘map 
staining’. Using the background of the map for visualizing the values mapped to 
individual molecular entities or group of entities (e.g. score of functional module 
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activities) results in colorful background of the network map that represents the 
data distribution pattern (Bonnet et al., 2015). All those approaches for data 
integration into the signaling maps described above allow to rationalize the 
information embedded into the data: compare samples or group of samples; find 
typical patterns of data distribution across the molecular mechanisms depicted on 
the maps; grasp deregulated ‘hot area’ on the maps and major involved players 
and draw hypothesis as to which mechanisms to concentrate the work in the 
samples under study. These signaling network-based molecular signatures of 
samples thus help to stratify patients or samples (Figure 5). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  A 
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Figure 5. NaviCell Web service. (A). General architecture of the NaviCell Web service server. 
Client software (light blue layer) communicates with the server (red layer) through standard 
HTTP requests using the standard JSON format to encode data (RESTful web service, dark blue 
layer). A session (with a unique ID) is established between the server and the browser (yellow 
layer) through Ajax communication channel to visualize the results of the commands send by the 
software client. (B). BC gene expression data integration and analysis using ACSN. The mRNA 
expression data from TCGA collection has been used for evaluation of functional modules 
activities and ACSN coloring as ‘map staining’ for four BC types. The four BC subtypes are 
characterized by different patterns of module activities.  
 
Various omics data are available on the public and local databases (Lapatas et al., 
2015). However, there are no tools that support import of big datasets from these 
databases and displaying them on signaling network maps in efficient way and 
with optimized visualization settings. To answer to this demand, we developed 
NaviCom, a python package and web interface for automatic simultaneous display 
of multi-level data in the context of signaling network map 
(http://navicom.curie.fr). NaviCom is bridging between cBioPortal database and 
NaviCell interactive tool for data visualization (http://navicell.curie.fr). NaviCom 
is empowered by a cBioFetchR R package to import high-throughput data sets 
from cBioPortal to NaviCell and navicom Python module allowing automatized 
simultaneous visualization of multi-level omics data on the interactive signaling 
network maps using NaviCell environment. NavCom proposes several 
standardized modes of data display on signaling networks maps to address specific 
biological questions (Dorel et al, in revision). (Figure 6A). 
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Figure 6. NaviCom. (A). General architecture of NaviCom environment. The NaviCom 
interface provides the user with an updated list of studies from cBioPortal and links to ACSN 
and NaviCell maps collections. When visualization is launched, NaviCom starts a new NaviCell 
session and calls a cgi on the server. The cgi downloads cBioPortal data to the NaviCell session 
and displays them to generate the molecular portrait selected by the user. (B). Molecular 
portrail of Breast Invasive Carcinoma (Nature 2012) from 825 samples visualized on ACSN 
Cell cycle map. Visualization settings: expression-map staining/ copy number-heat map/ 
mutations-blue triangle/ methylation-pink diamond/proteomics-yellow circle. 
 
This tool enables generation of complex molecular portraits from multiple omics 
datasets from cBioPortal. We aim to create signaling network-based molecular 
portrait for each disease and studied samples in the context of ACSN or any map 
prepared in NaviCell format (Figure 6B).  
B C
D 
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In near future the NaviCom platform will be extended and will provide access to 
any type of omics data from wide range of databases (TCGA, ICGC, HGMB, 
METABRIC, CCLE). In addition, to allow broader description of molecular 
mechanisms implicated in studied sample, signaling networks available in 
databases as Kegg (Kanehisa et al., 2012), Reactome (Croft et al., 2010) and 
others, will be also integrated and used for high-throughput data analysis via 
NaviCom platform. 
 
I lead this ongoing muntidisciplinary project and supervise the activities of the team. During 
the projects, five original papers, one book chapter; dozen of proceedings; press releases on 
the developments have been published. Some of the papers were selected to the highlights 
talks at international computational biology conferences and were topics for invited seminars. 
The project has been awarded by the “Thought leader award” grant from Agilent supporting 
the ongoing collaboration with the Agilent Genespring team for integration of 
ACSN/NaviCell and GeneSpring features. ACSN, NaviCell and NaviCom are in the process 
of joining the Garuda Alliance (http://www.garuda-alliance.org), the integrative international 
platform for systems biology and biomedical research and also the basis for numerous 
collaborative projects. 
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3.	  NETWORK	  MODELING	  IN	  PRE-­‐CLINICAL	  RESEARCH	  
 
Institut Curie, Paris, France 
 
CHAPTER	  AT	  GLANCE	  
This chapter is dedicated to applications of signaling networks for basic research and pre-
clinical studies. In the first project we created differential network-based molecular signatures of 
sensitivity of two DNA repair interfering drugs. This study allowed us to suggest drugs synergy 
that has been confirmed for breast cancer cell lines. In the second example, I show how network 
analysis and modeling help to reveal key regulators of invasion. The prediction allowed to 
develop the transgenic mice model of early invasive colon cancer. In the third project, we 
performed a structural analysis of signaling network together with omics data from ovary cancer 
patients resistant to genotoxic treatment. Following this study we retrieved synthetic lethal gene 
sets and suggested intervention combinations to restore sensitivity to the treatment. The 
approaches developed for these projects represent a more general paradigm applicable for other 
studies. 
	  
3.1	  Explaining	  synergistic	  effect	  of	  combined	  treatment	  in	  cancer	  
Working hypothesis  
Using DNA repair inhibitors to target cancer cells is a promising therapy but its 
application is limited by the compensatory activities of different repair pathways. 
For example, PARP inhibitors that act as synthetic lethal with BRCA deficiency, 
appear however less efficient in patients with active Homologous Recombination 
(HR) repair (Lord et al., 2015). During treatment, some tumors escape through 
compensatory mutations that restore the HR activity or stimulate the activity of 
alternative repair pathways such as Non-homologous End Joining (NHEJ).  
A new class of DNA repair pathways inhibitor (Dbait or DT01) has been recently 
developed, consisting of 32bp deoxyribonucleotides DNA double helix that 
mimics double strand breaks (DSB). It acts as an agonist of DNA damage 
signaling thereby inhibiting DNA repair enzyme recruitment at the damage site 
(Quanz et al., 2009). However, study of Dbait effects on multiple types of cancer 
cell lines shows occurrences of resistance in cancer type-independent manner. 
Since such promising treatments are facing some hurdles including acquired 
resistance, finding sensitizing agents to restore response to treatment in cancer is 
needed.  
 
Methodologies and Results 
Depending on genetic background, different breast cancer tumors vary in their 
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sensitivity to DNA repair inhibitors, as PARP inhibitors and Dbait. To understand 
molecular mechanisms underlining these differences, a combination of 
experimental and bioinformatics approaches was applied. Triple Negative Breast 
Cancer (TNBC) cell lines were studied for their sensitivity to Dbait (DT01) and 
the PARP inhibitor Olaparib showing wide distribution of responsiveness to these 
drugs, that in many cases in not correlated (Figure 7A). We performed integrative 
analysis of omics data from these cell lines covering mRNA expression, copy 
number variations and mutational profiles and found that at least 70 non-
overlapping genes were robustly correlated with sensitivity to each one of the 
drugs (not shown). Analysis of the omics data in the context of ACSN maps 
confirms that different specific defects in DNA repair machinery are associated to 
Dbait or Olaparib sensitivity (Figure7B). In addition, we identified group of 
deregulated functional modules across ACSN specifically associated with each 
one of the drugs and established a predictive drug response network-based 
molecular portraits. These molecular signatures highlighted different involvement 
of mechanisms between cells sensitive/resistant to Dbait and Olaparib, suggesting 
a rational for combination of these two drugs. We confirmed synergistic 
therapeutic effect of the combined treatment with Dbait and PARP inhibitors in 
TNBC, while sparing healthy tissue (Figure 7C) (Jday et al., in preparation). 
 
Figure 7.  Sensitivity of TNBC cell lines combination of DNA repair inhibitors. (A). 
Correlation analysis of survival to DT01 and Olaparib in TNBC and control cell lines. (B). 
Molecular portraits of DT01 and Olaparib sensitive/resistant TNBC cell lines visualized on 
Olaparib [µM] 
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DNA repair map. (C). Cell survival to combination of DT01 and Olaparib. With DT01(black 
line), without DT01(grey line),dashed lines indicate calculated cell survival for additive effect of 
two drugs. 
 
In this ongoing project I supervise scientific activity of a technician and co-supervise a PhD 
student.  
 
3.2	   Finding	   metastasis	   inducers	   in	   colon	   cancer	   through	   network	  
analysis	  
Working hypothesis  
Evolution of invasion and metastasis, in particular in colon cancer, has been 
studied in experimental models, however, the mechanism that triggers the process 
is still not clear and the available mice models of colon cancer are far from being 
satisfactory (Hung et al., 2010, Trobridge et al., 2009). With aim to create an 
experimental mouse model of invasive colon cancer, one needs to address the 
question what are the major players and the driver mutations inducing invasion. 
One of early events of metastasis is assumed to be epithelial to mesenchymal 
transition (EMT) (Nieto, 2011).  
 
Methodologies and Results 
In order to identify interplay between signaling pathways regulating EMT, we 
manually created a signaling network in CellDesigner tool (Kitano et al., 2005) 
based on the information retrieved from around 200 publications (Figure 8A). This 
signaling map is now integrated into the ACSN. We performed structural analysis 
and simplification of the EMT network that highlighted the following EMT 
network organization principles, which is in agreement with current EMT under- 
standing: (1) Five EMT transcription factors SNAIL, SLUG, TWIST, ZEB1 and 
ZEB2 that have partially overlapping sets of downstream target genes can activate 
the EMT-like program. (2) These key EMT transcription factors are under control 
of several upstream mechanisms: they are directly induced at the transcriptional 
level by the activated form of Notch, NICD, but are downregulated at the 
translational level by several miRNAs (namely, mir200, mir34, mir203 and 
mir192) that are under transcriptional control of p53 family genes. Interestingly, 
some key EMT transcription factors can inhibit microRNAs, in this way 
sustaining their own activation. (3) According to the network structure, all five 
key EMT transcription factors should be activated ensuring simultaneous 
activation of EMT-like programme genes and downregulating miRNAs. In 
addition, the EMT key inducers also inhibit apoptosis and reduce proliferation. (4) 
The activity of Wnt pathway is stimulated by transcriptional activation of the gene 
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coding for b-catenin protein by Notch-induced TWIST or SNAI1. The Wnt 
pathway, in turn, can induce the expression of Notch pathway factors, creating a 
positive feedback loop. In agreement with other studies, the Wnt pathway does not 
directly induce EMT, but helps to maintain it. (5) Components of the Wnt and 
Notch pathways are negatively regulated by miRNAs induced by the p53 family 
(p53, p63 and p73). The balance between the effect of positive (Notch and Wnt) 
and negative (p53, p63 and p73 mediated by miRNAs) regulatory circuits on EMT 
inducers dictates the possibility of EMT phenotype (Knouf et al., 2012, Moes et 
al., 2012, Siemens et al., 2011, Fre et al., 2009). 
 
Based on those features of the network we performed network complexity 
reduction using BiNoM up to core regulators of EMT, apoptosis and proliferation 
that were preserved through all levels of reduction (Bonnet et al., 2013). The 
reduced network has been used for comparison between the wild type and all 
possible combinations of single and double mutants for achieving EMT-like 
phenotype (Figure 8B,C).  
 
We predicted that in Apc-/-/p53-/- double mutant, Wnt activation does not induce 
EMT, because p63/p73 induced microRNAs can still inhibit the Wnt and Notch 
pathway. When Notch is activated in an Apc-/- background, cell proliferation is 
increased as has been observed in the mice models. At the same time, EMT is 
inhibited by the microRNA expression induced by, resulting in non-invasiveness. 
This explains the observed absence of metastases in NICD/Apc-/- mice. Finally, in 
NICD/p53-/- double mutant, other members of p53 family cannot rescue the 
function of p53 anymore as constitutively activated Notch inhibits the activity of 
both p63 and p73. NICD activates the transcription of the EMT key inducers and 
inhibits the production of microRNAs by suppressing p63/p73 in the context of 
p53-/-. Notch and p53 have opposite effects on EMT inducers, and overexpression 
of NICD and knocking-out p53 should have synergetic effect. Furthermore, EMT 
inducers may activate the Wnt pathway, possibly resulting in a positive feedback 
loop that will amplify Notch activation and maintain an EMT-like program. 
Therefore, our computational analysis of the signaling network leads to the 
prediction that the simultaneous activation of Notch and loss of p53 can promote 
an EMT-like phenotype (Figure 8D, E). 
 
To validate this hypothesis, we created a transgenic mouse model expressing a 
constitutively active Notch1 receptor in a p53- deleted background, specifically in 
the digestive epithelium. Importantly, green fluorescent protein (GFP) expression 
linked to the Notch1 receptor activation allows lineage tracing of epithelial tumor 
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cells during cancer progression and invasion (Figure 8F). These mice develop 
digestive tumours with dissemination of EMT-like epithelial malignant cells to the 
lymph nodes, liver and peritoneum and generation of distant metastases (Figure 
8G). We have explored early inducers of the EMT program in human disease and 
confirmed in invasive human colon cancer samples that EMT markers are 
associated with modulation of Notch and p53 gene expression in similar manner 
as in the mice model (Figure 8H), supporting a synergy between these genes to 
permit EMT induction (Chanrion et al., 2014).  
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Figure 8. Prediction of synthetic interaction combination to achieve invasive phenotype in 
colon cancer mice model (A) Comprehensive signaling network of EMT regulation; (B). 
Scheme representing major players regulating EMT after structural analysis and reduction of 
signaling network complexity; (C) and (D) Mechanistic model explaining EMT inducers 
regulation involving Notch, p53 and Wnt pathways; (E) Phenotypes in single and double 
mutants; (C) Lineage tracing of cell in tumor and in distant organs; (F) Immunostaining for 
major EMT markers; (G) Regulation of p53, Notch and Wnt pathways in invasive colon cancer 
in human (TCGA data). 
Our prediction of synthetic interaction between Notch and p53 demonstrated that 
there are alternative ways to reach permissive conditions to induce EMT, in 
addition to those already described in the literature. This idea was not intuitive and 
actually contradictory to the commonly accepted dogma in the colon cancer field. 
The study evokes an important message that gathering cell signaling mechanisms 
together may undercover un-expected interactions and lead to discovery of new 
mechanisms in regulation of cell phenotypes that may significantly affect the 
understanding of basic molecular processes implicated in cancer and change the 
therapeutic approaches. In addition, the comprehensive EMT signaling network is 
reach resource of information can be used in further studies. Finally, the new EMT 
mice is a relevant model mimicking the invasive human colon cancer and a system 
for therapeutic drugs discovery (Kuperstein et al., 2015).  
 
In this project I supervised scientific activity of one postdoc. The projects resulted in 
publication of two papers, several proceedings and press communication. Some of those 
papers were selected to the highlights talks at international computational biology 
conferences and were topics for invited seminars.  
 
3.3	   Complex	   intervention	   gene	   sets	   derived	   from	   data-­‐driven	  
network	  analysis	  for	  cancer	  patients	  resistant	  to	  genotoxic	  treatment	  
 
Working hypothesis 
The idea of SL treatment approach is to take an advantage of the specificities in 
tumor cells which display abnormal expression or function of one gene from 
synthetic lethal pair. Targeting synthetic lethal partner allows then selective killing 
of tumor cells (McLornan et al., 2014). This approach is applied in BRCA2 
mutated breast canser cases using PARP inhibitors, however there is frequent 
escape from the treatment, requiring to more complex solution. One of the reasons 
for treatment failure is the robustness of cell signaling network ensured by 
redundant mechanisms that provide the possibility to bypass drugs effect (Dietlein 
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et al., 2014). Therefore the ways for identifying and blocking those active 
compensatory pathways should be found.  
 
One of the approaches is taking into account the signaling network structure and 
find the most optimal synthetic lethal combinations of genes (most probably more 
than pairs) (Huang et al., 2014, Acencio et al., 2013, Zeng et al., 2014). Thus, 
analyzing synthetic lethal (SL) combinations in the context of patien’s omics data 
as mutation profile, genome, transcriptome, epigenome, etc. to prioritize and chose 
the appropriate SL set of genes. These analyses may contribute to network-based 
patients stratification and prediction of sensitivity to traditional drugs, but also 
help suggesting rationalized treatment schemes adjusted to each patient. 
 
Methodologies and results 
Genotoxic treatment as Cisplatin, that induces un-repairable DNA damage and cell 
death specifically in cancer cells, is often inefficient due to backup mechanisms in 
the DNA repair signaling. To overcome Cisplatin resistance in ovarian cancer, we 
looked for synthetically interacting combinations of genes to suggest intervention 
gene sets.  
 
A comprehensive map of cell cycle and DNA repair signaling network constructed 
from literature curation was used for this study 
(https://acsn.curie.fr/navicell/maps/dnarepair/master/index.html).  The map is 
composed of three interconnected cell cycle, DNA repair and checkpoints layers 
covering the most recent knowledge on molecular mechanisms implicated in these 
processes (Kuperstein et al., 2015). We derived a state transition graph from the 
map including all paths leading to repaired DNA and genes regulating each step 
(Figure 9A). Using OCSANA algorithm for searching the minimal cut sets (MCS) 
on the state transition graphs, considering genes that regulate each step as potential 
target for interference (Vera-Licona et al., 2013), we identified MCSs whose 
knock-out completely abort DNA repair (Figure 9B). The coherence of the method 
has been validated using experimentally–proven SL pairs, verifying the 
enrichment of the SL pair in real vs. randomly-generated (pseudo)-MCSs (Figure 
9C).  
 
For selection of the best MCS to be targeted, we need to find those where part of 
the components are already altered in the patient, allowing to exploit this 
background and targeting the remaining components in the set, achieving synthetic 
lethality. MCSs were evaluated for each patient (TCGA ovarian cancer dataset) 
using genomic, expression and mutation data integration and correlation with 
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patient’s resistance/sensitivity to Cisplatin. The top-correlated MCSs were ranked 
according for the mutation status of each gene. Those MCSs that were enriched 
with genes harboring inactivating mutations, were suggested as best intervention 
combinations to restore sensitivity to Cisplatin by inhibiting the remaining ‘active’ 
genes in the set (Figure 9C, table insert). This approach is relevant for 
complementing genotoxic chemotherapy by targeting specifically cancer cells and 
exploiting certain defects in the DNA repair machinery in each patient (Russo et 
al., in preparation). 
 
 
 
Figure 9. Intervention gene sets for Cisplatin-resistant ovary cancer patients. (A). 
Comprehensive map of DNA repair. (B). State transition graph of DNA repair map with 
regulators of each state transition (regulators of level 1). (C). Enrichment of SL from shRNA 
screen lines (DECIPHER project) in ‘real’ vs. pseudo-MCSs. (D). Projection of top 3 principal 
components of TCGA ovarian cancer patients groups associated with unique MCSs.  Survival 
curves comparing Cisplatin resistant and sensitive patients associated with unique MCS sets. 
Table: Top 5 intervention sets for Cisplatin resistant and sensitive groups (green-inhibited gene, 
red-activated gene). 
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4.	  COMPEX	  SYNTHETIC	  INRETACTION	  MECHANISMS	  	  
 
Institut Curie, Paris, France 
 
CHAPTER	  AT	  GLANCE	  
This chapter discusses various aspects of synthetic interactions in cell signaling. The first part of 
the chapter describes how the mathematical modeling of homologous recombination pathway 
combined with the analysis of synthetic lethal screens lead to discovery of a new type of 
synthetic lethality mechanism. The second part reviews different models of synthetic lethality 
mechanisms at several scales, starting from molecular complexes, through molecular pathways 
and up to the functional modules and different cell types. Taking into consideration this 
systematic knowledge will help to significantly broaden the canonical interpretation of synthetic 
interactions, in particular synthetic lethality, with direct implications to molecular pathways 
understanding and therapy approaches. 
 
4.1	  Kinetic	  trap	  of	  a	  pathway:	  new	  mechanism	  of	  synthetic	  lethality	  
 
Working hypothesis  
The classic interpretation of synthetic lethality stipulates that two synthetic lethal 
genes work in parallel, mutually compensatory pathways (Bandyopadhyay et al., 
2010). However, a significant number of synthetic interactions are caused by 
defects in genes participating in the same molecular pathway (Michaut et al., 
2011). The canonical interpretation of pathways assumes only forward 
propagation. However, the view of molecular pathways as unidirectional, linear 
reaction cascades is too simplistic. Pathway steps can be reversible which leads to 
forward and backward propagation of molecular events along the pathway and 
increases robustness and fidelity of the process.  
 
Methodologies and results 
The homologous recombination DNA repair pathway is one of the rare examples 
of a pathway were forward and backward steps are well described (Heyer et al., 
2010). In addition, it has been recently shown that one of the intermediates of 
homologous recombination process is toxic to cells if accumulates above certain 
concentration for sufficient time period (Figure 10A).  
 
To better understand the system properties of genetic relationships in this 
pathway, we represented homologous recombination (HR) in a form of simplest 
model of DNA repair pathway with reversible steps and alternative compensatory 
pathway. The simplest model contains three statuses of DNA (Substrate-damaged 
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DNA, Intermediate, Product-repaired DNA) (Figure 10B). We performed 
analytical study of dynamic features using the simplest linear mathematical model 
(Figure 10C). We have recapitulated observed genetic scenarios, among others, 
classical synthetic lethality between pathways (BRCA2-PARP) and the RAD54 
mutants that refers to the situation when genetic background dictates susceptibility 
to accumulation of genetic instability (Figure 10D). We proposed a novel 
mechanism, within-reversible-pathway synthetic lethality that involves reversible 
pathway steps, catalyzed by different enzymes in the forward and backward 
directions. The cell death happens due to kinetic trapping of a pathway into the 
step resulting in toxic intermediate accumulation because of the mutations in the 
enzymes catalyzing ‘in’ and out’ reactions (Figure 10D, scenario ‘4’). The 
prediction has been validated in Srs2-Rad54 mutants in yeast, where one of the 
intermediates of homologous recombination process is toxic to cells if 
accumulates above certain concentration for sufficient time period due to 
invalidating mutations of the Srs2 and Rad54, catalyzing ‘in’ and ‘out’ reactions 
of the corresponding step. 
In order to assess the probability of appearance of within-pathway synthetic 
lethality in other processes, we ranked all pathways from the KEGG database 
(Kanehisa et al., 2012) according to their normalized proportion of synthetic lethal 
interactions within the pathway calculated using yeast gene interaction screen 
results (Costanzo et al., 2010). Interestingly, HR ranks at the top among DNA 
repair pathways (Figure 10E).  
 
There is considerable evidence that many molecular pathways include reversible 
steps catalyzed by different enzymes in the forward and backward directions. Any 
of those processes can be theoretically trapped into one of their intermediate states 
if two regulators of forward and backward steps are inactive. In these cases, 
kinetic trap can be due to the accumulating intermediate or blockade of proper 
signal propagation or perturbed resource recycling, etc. (Figure 10F). 
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Figure 10. Kinetic trap model of synthetic lethality within a single reversible pathway. (A). 
DNA repair pathway with reversible step. (B). Abstract representation of Homologous 
recombination (HR) pathway with reversible steps, containing substrate (S), intermediate (I), 
product (P) and alternative, compensatory pathway. (C). Pathway steady states for various 
combinations of parameters in the mathematical model of DNA repair with reversible steps and 
a toxic intermediate. (D). Modeling possible scenarios of single and double synthetic lethal 
mutations in the simplest model. The edge thickness denotes the relative speeds between 
different states of DNA. Scenario ‘4’ represents within singe pathway kinetic trap model of 
synthetic lethality. (E). Normalized proportion of synthetic lethal interactions within single 
pathway across KEGG pathway database, calculated using data on the genome-wide screening 
of genetic interactions in yeast (Costanzo et al., 2010). (F). Examples of molecular processes 
with alternative pathways and potential to kinetic trap into a toxic intermediate. 
 
These results significantly broaden the interpretation of synthetic lethal effects, 
which fundamentally impacts on understanding of pathways propagation in the 
cell. The concept of synthetic lethality has been applied to cancer therapy, and our 
modeling results suggest new cancer therapy, targeting a single pathway to induce 
synthetic lethality in pathological cells by trapping reversible pathways into the 
step where toxic intermediates will accumulate in cancer cells (Zinovyev et al., 
2013). 
 
4.2	  Synthetic	  lethality	  mechanisms	  and	  organizational	  principles	  of	  
cell	  signaling	  at	  different	  scales	  
 
Working hypothesis  
Availability of high-throughput techniques makes it possible to assay genetic 
interactions of many genes in parallel in systematic way (high-throughput 
screens). This data on genetic interactions together with the latest findings on 
signaling and metabolic pathways helps building higher level models of cell 
organization and discovering new mechanisms of synthetic interactions. Despite 
systematic phenomenological classification of genetic interactions, we still lack an 
exhaustive classification of the mechanistic principles of the extreme case of 
negative genetic interaction, synthetic lethality. We describe mechanisms of 
synthetic lethality at several scales, starting from molecular complexes, through 
molecular pathways and up to the level of functional modules and cells. 
 
Methodologies and results 
Synthetic lethal interactions are frequently observed within or between members 
of molecular complexes. Absolute loss of catalytic activity in the essential 
complex may result in cell death (Figure 11A). It was estimated that among all 
synthetic lethal genetic interaction pairs, 9-14% belong to the same biological 
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pathway. The mechanisms explaining synthetic lethal interactions in the same 
pathway vary depending on the architecture of the pathway. There are synthetic 
lethal mechanisms as defect accumulation, internal redundancy, intrinsic buffering 
and kinetic trap (Figure 11B).  
The most known interpretation of synthetic lethality is when two genes function in 
parallel pathways that collectively contribute to a common essential biological 
function. However, in a view of recent findings, this classical paradigm of 
between pathways synthetic lethality was extended and can be subcategorized in 
three classes of synthetic lethality mechanisms as redundancy, buffering and 
synergy (Figure 11C). 
The phenotype readout used in the large-scale genetic screenings is the cell 
growth, which is complex phenotype with many cellular functions contributing. 
Cell growth is a combination of cell death, cell replication and cell senescence 
rates, etc. and each of these processes can be addressed as an independent 
phenotype. Moreover, it is possible to study phenotypes not directly connected to 
cell growth. Clustering of genes by functional similarity led to the observation that 
synthetic interactions are more frequent between functional modules with related 
biological functions rather than between functional modules that have independent 
cellular roles. For example, genes involved in the functional module of cell 
polarity more frequently have synthetic interactions with genes involved into the 
cytoskeleton remodeling module. Genes related to the checkpoints module 
synthetically interact with the genes from the sister-chromatid cohesion, DNA 
replication and DNA repair module. Genes responsible for protein folding 
synthetically interact with the genes from Endoplasnatic reticulum (ER) module, 
etc. Therefore, it is more probable to anticipate synthetic lethal combinations in 
functionally-related modules (Figure 11D, upper panel). 
In cancer biology, many phenotypes contributing to the disease, are dictated by 
different cells. For example, phenotypes as Epithelial-Mesenchymal Transition 
(EMT), different modalities of cell death (apoptosis, necrosis), types of DNA 
repair mechanisms (single strand, double strand, stalled replication fork) are 
mostly related to cancer cell. Whereas immune response (innate, adaptive), 
vascularization signaling (angiogenesis), etc., are dictated by different types of 
cells. Synthetic interactions at the level of different cell type should be considered. 
Systematic description of orchestration between these players will allow to point 
to multi-phenotypic synthetic lethality (Figure11D, lower panel). (Kuperstein et 
al., in preparation). 
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Figure 11. Mechanisms of synthetic lethality as different scales of cell signaling. 
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CONCLUSIONS 
 
A fundamental question of signaling regulation in human disorders can be 
addressed by experimental and computational approaches, together helping to 
understand the principles of signaling rewiring. It will have an impact on 
personalized intervention schemes, in particular those based on combination of 
drugs.  
 
Organization and formal representation of the knowledge of cell signaling 
followed by analysis of network features will provide a more global view on 
molecular mechanisms and will facilitate modeling of cell fates. It has a potential 
to explain mutant phenotypes, and reveal new molecular interactions. Considering 
the topology of signaling networks and studying network perturbations together 
with high-throughput data can guide us toward an optimal intervention strategy in 
patients or in studied experimental systems. 
 
Current advances in systems biology and systems medicine allow a standard, 
unambiguous representation of molecular processes involved in different human 
diseases, providing a comprehensive platform to interpret experimental results. 
The collective research effort on different human disorders will lead to the 
identification of emerging disease hallmarks (Mazein et al., in preparation). 
 
Typical systems biology project workflow 
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